Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Florida launches brain disease biobank to fuel future discoveries

NCT ID NCT05491980

Knowledge-focused Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 2 times

Summary

This study is creating a statewide collection of blood samples and medical information from people with various brain blood vessel diseases, such as stroke and dementia. The goal is to build a resource that scientists can use in future research to better understand and potentially treat these conditions. About 72 participants are providing data and samples, but no new treatments are being tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

72 people

The number who actually took part.

Started

Aug 2022

Expected to finish

Jun 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects identified with a history of cerebrovascular disease will be recruited from both the in-patient and outpatient services at Mayo Clinic Florida.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: • Affected subjects with diverse cerebrovascular conditions, including, but not limited to, ischemic stroke, transient ischemic attack (TIA), intracerebral hemorrhage (ICH), aneurysmal subarachnoid hemorrhage (aSAH), vascular dementia (VAD), anoxic brain injury, unruptured intracranial aneurysm (UIA), cavernous malformation, arteriovenous malformations (AVM), carotid and vertebral arterial dissections, symptomatic and asymptomatic cervical carotid artery atherosclerotic stenosis, non-aneurysmal perimesencephalic subarachnoid hemorrhage (naSAH), cerebral venous thrombosis (CVT), moyamoya disease, fibrosmuscular dysplasia (FMD), non-traumatic, angiography-negative subarachnoid hemorrhage, leukoaraiosis, arteriovenous fistula, reversible cerebral vasoconstriction syndrome (RCVS), and CADASIL. Exclusion Criteria: • All patients with the following known or suspected virulent microorganisms causing an active or latent infection will be excluded from the study: * Human immunodeficiency virus (HIV); * Any viral hepatitis; * West Nile virus (WNV); * Influenza virus; * Tuberculosis (TB); * Any bacteremia; * Any fungemia; * Any prionopathy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aneurysmal subarachnoid hemorrhage are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain aneurysm brain hypoxia - ischemia carotid stenosis cerebral arteriopathy with subcortical infarcts and leukoencephalopathy cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 cerebral sinovenous thrombosis cerebrovascular disorder congenital arteriovenous fistula fibromuscular dysplasia intracerebral hemorrhage intracranial thrombosis ischemic stroke Leukoaraiosis Moyamoya disease reversible cerebral vasoconstriction syndrome subarachnoid hemorrhage transient ischemic attack vascular dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aneurysmal subarachnoid hemorrhage Anoxic brain injury Arteriovenous fistula Asymptomatic carotid artery stenosis Cadasil Carotid artery stenosis symptomatic Cerebral venous thrombosis Cerebrovascular disease Fibromuscular dysplasia Intracerebral hemorrhage Ischemic stroke Leukoaraiosis Moyamoya disease Non-aneurysmal perimesencephalic subarachnoid haemorrhage Reversible cerebral vasoconstriction syndrome Subarachnoid hemorrhage Transient ischemic attack Unruptured intracranial aneurysm Vascular dementia

Contacts and locations

Locations

  • Mayo Clinic Florida

    Jacksonville, Florida, 32224, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.